WallStreetZenWallStreetZen

NASDAQ: MRNA
Moderna Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for MRNA

Based on 6 analysts offering 12 month price targets for Moderna Inc

Min Forecast
$34.00-57.37%
Avg Forecast
$48.83-38.78%
Max Forecast
$77.00-3.46%

Should I buy or sell MRNA stock?

Based on 6 analysts offering ratings for Moderna Inc.

Hold
Strong Buy
1 analysts 16.67%
Buy
0 analysts 0%
Hold
4 analysts 66.67%
Sell
1 analysts 16.67%
Strong Sell
0 analysts 0%
Our proven Zen Rating quant model agrees with analyst consensus with a "Hold" rating. Learn More

Be the first to know when Wall Street analysts revise their MRNA stock forecasts and price targets.

MRNA stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-06-26
lockedlocked$00.00+00.00%2026-06-08
lockedlocked$00.00+00.00%2026-05-04
lockedlocked$00.00+00.00%2026-05-04
lockedlocked$00.00+00.00%2026-05-04
RBC Capital
Top 8%
93
HoldMaintains$38.00-52.36%2026-05-04

1 of 1

Forecast return on equity

Is MRNA forecast to generate an efficient return?

Company
5.53%
Industry
92.26%
Market
174.26%
MRNA's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is MRNA forecast to generate an efficient return on assets?

Company
3.57%
Industry
27.65%
MRNA is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

MRNA earnings per share forecast

What is MRNA's earnings per share in the next 3 years based on estimates from 27 analysts?

Avg 1 year Forecast
-$8.85
Avg 2 year Forecast
-$5.11
Avg 3 year Forecast
-$3.18

MRNA revenue forecast

What is MRNA's revenue in the next 3 years based on estimates from 27 analysts?

Avg 1 year Forecast
$2.1B-4.18%
Avg 2 year Forecast
$2.4B+10.07%
Avg 3 year Forecast
$3.0B+35.33%
MRNA's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

MRNA revenue growth forecast

How is MRNA forecast to perform vs Biotechnology companies and vs the US market?

Company
10.03%
Industry
34.29%
Market
13.95%
MRNA's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
MRNA's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

MRNA vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
MRNA$79.76$48.83-38.78%Hold
ONC$297.65$388.00+30.35%Strong Buy
RPRX$57.77$61.00+5.59%Strong Buy
ROIV$35.13$38.60+9.88%Strong Buy
INSM$111.60$206.00+84.59%Strong Buy
View Top Biotech Stocks

Moderna Stock Forecast FAQ

Is Moderna Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 6 Wall Street analysts covering (NASDAQ: MRNA) stock is to Hold MRNA stock.

Out of 6 analysts, 1 (16.67%) are recommending MRNA as a Strong Buy, 0 (0%) are recommending MRNA as a Buy, 4 (66.67%) are recommending MRNA as a Hold, 1 (16.67%) are recommending MRNA as a Sell, and 0 (0%) are recommending MRNA as a Strong Sell.

If you're new to stock investing, here's how to buy Moderna stock.

What is MRNA's earnings growth forecast for 2026-2028?

(NASDAQ: MRNA) Moderna's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.58%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34.17%.

Moderna's earnings in 2026 is -$3,194,000,000.On average, 27 Wall Street analysts forecast MRNA's earnings for 2026 to be -$3,511,558,392, with the lowest MRNA earnings forecast at -$3,686,303,061, and the highest MRNA earnings forecast at -$3,133,024,301. On average, 26 Wall Street analysts forecast MRNA's earnings for 2027 to be -$2,027,776,177, with the lowest MRNA earnings forecast at -$2,598,672,246, and the highest MRNA earnings forecast at -$1,374,864,387.

In 2028, MRNA is forecast to generate -$1,260,947,052 in earnings, with the lowest earnings forecast at -$2,364,211,246 and the highest earnings forecast at -$574,943,289.

What is MRNA's revenue growth forecast for 2026-2028?

(NASDAQ: MRNA) Moderna's forecast annual revenue growth rate of 10.03% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.29%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.95%.

Moderna's revenue in 2026 is $2,225,000,000.On average, 27 Wall Street analysts forecast MRNA's revenue for 2026 to be $845,948,304,188, with the lowest MRNA revenue forecast at $753,497,105,841, and the highest MRNA revenue forecast at $960,619,533,039. On average, 26 Wall Street analysts forecast MRNA's revenue for 2027 to be $971,729,548,291, with the lowest MRNA revenue forecast at $753,100,319,582, and the highest MRNA revenue forecast at $1,319,711,097,434.

In 2028, MRNA is forecast to generate $1,194,723,425,849 in revenue, with the lowest revenue forecast at $852,296,884,332 and the highest revenue forecast at $1,630,394,738,231.

What is MRNA's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: MRNA) forecast ROA is 3.57%, which is lower than the forecast US Biotechnology industry average of 27.65%.

What is MRNA's Price Target?

According to 6 Wall Street analysts that have issued a 1 year MRNA price target, the average MRNA price target is $48.83, with the highest MRNA stock price forecast at $77.00 and the lowest MRNA stock price forecast at $34.00.

On average, Wall Street analysts predict that Moderna's share price could fall to $48.83 by Jun 26, 2027. The average Moderna stock price prediction forecasts a potential downside of 38.78% from the current MRNA share price of $79.76.

What is MRNA's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: MRNA) Moderna's current Earnings Per Share (EPS) is -$8.15. On average, analysts forecast that MRNA's EPS will be -$8.85 for 2026, with the lowest EPS forecast at -$9.29, and the highest EPS forecast at -$7.90. On average, analysts forecast that MRNA's EPS will be -$5.11 for 2027, with the lowest EPS forecast at -$6.55, and the highest EPS forecast at -$3.47. In 2028, MRNA's EPS is forecast to hit -$3.18 (min: -$5.96, max: -$1.45).

What is MRNA's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: MRNA) forecast ROE is 5.53%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.